Adicet Bio, Inc.
Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States
Website: http://www.adicetbio.com/
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
58 articles with Adicet Bio, Inc.
-
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors
11/18/2021
Adicet Bio, Inc. today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors.
-
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting
11/12/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the presentation of new preclinical data supporting its Glypican-3 (GPC3) targeted allogeneic, off-the-shelf gamma delta chimeric antigen receptor (CAR) T cell development candidate for solid tumors at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates
11/10/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the third quarter ended September 30, 2021.
-
Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference
11/8/2021
Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference taking place on November 15-17, 2021.
-
Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting
11/4/2021
Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced that a Trials in Progress abstract related to the Company’s lead candidate, ADI-001, has been accepted for an oral presentation at the 63rd American Society of Hematology Annual Meeting and Exposition being held December 11-14, 2021.
-
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
10/12/2021
Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer.
-
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
10/4/2021
Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting to be held November 10-14, 2021.
-
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
9/13/2021
Twist Bioscience Corporation and Adicet Bio, Inc. today announced a collaboration to accelerate the discovery of gamma delta T cell therapies against five undisclosed targets.
-
Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
9/13/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, and Twist Bioscience Corporation (NASDAQ: TWST),
-
Adicet Bio to Participate in Upcoming Investor Conferences in September 2021
9/2/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that company management will participate in two upcoming virtual investor conferences in September.
-
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
8/12/2021
Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, reported operational highlights and financial results for the second quarter ended June 30, 2021.
-
Adicet Bio to Participate in Upcoming Investor Conferences - Aug 02, 2021
8/2/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that company management will participate in three upcoming virtual investor conferences in August.
-
Adicet Bio Announces Formation of Scientific Advisory Board
7/15/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the formation of a Scientific Advisory Board.
-
Adicet Bio Added to the Russell 2000® Index
6/28/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that the Company has been added to the Russell 2000® Index, effective June 28, 2021, as part of the 2021 Russell indexes annual reconstitution.
-
Adicet Bio to Participate in Upcoming Investor Conferences - May 18, 2021
5/18/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that company management will participate in two upcoming virtual investor conferences in May and June.
-
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
5/17/2021
Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021
-
Adicet Bio to Participate in Fireside Chat at the 7th Annual Truist Securities Life Sciences Summit
4/29/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will present at the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021 at 2:40 PM ET.
-
Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
4/15/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.
-
Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
4/13/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Blake Aftab, Ph.D., as Vice President of Research.
-
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/11/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.